Two randomised, placebo-controlled, double-masked, multicentre, 24-month studies (BPD OCR 003 AMD, or Verteporfin in Photodynamic Therapy-AMD [ VIP-AMD ], and BPD OCR 013, or Visudyne in Occult Choroidal Neovascularisation [ VIO ]) were conducted in patients with AMD characterised by occult with no classic subfoveal CNV.
Pri bolnikih z AMD, za katero je bila značilna okultna CNV brez klasične subfovealne CNV, so izvedli dve randomizirani s placebom kontrolirani dvojno maskirani multicentrični 24- mesečni študiji (BPD OCR 003 AMD ali Verteporfin in Photodynamic Therapy- AMD [ VIP- AMD ] in BPD OCR 013 ali Visudyne in Occult Choroidal Neovascularization [ VIO ].